BA.2.75.2 may be “a” concern, but it’s not “the” concern.
What is worrying is the trend that happened in the last few months in Omicron, and more robust in the polytomy of BA.2.75 - The RBD region, which was highly conserved in the past, shows increasing plasticity.
1/4
Published today: @TheLancet Commission on Covid-19:
"a massive global failures" with recommendations going forward
https://t.co/RI7wC2OjCF
It's a 57-page paper. I think this Figure and the 1-pager editorial summarize it well
With #ESMO22 turning to history, on the plane back to 🇬🇷, Ι added a column of main outcomes/potential clinical relevance in my previous list of influential trials in #NSCLC
🙏@myESMO staff, officers,speakers,chairs, attendees for a magical experience!
@OncoAlert#some#LCSM
Probably the most awaited trial #ESMO22. CODEBREAK200 (sotorasib vs doc in 2/3L NSCLC)
✅PFS HR 0.66 (5.6 vs 4.5 m / 24.8 vs 10.1% at 1 yr)
✅ORR 28.1 vs 10.2 %
❎OS HR 1.01
✅fewer gr. ≥3 & serious TRAEs
Endless discussion regarding the magnitude of benefit awaited @OncoAlert
Nivo IPI adjuvant RCC is negative. Larger than life @motzermd presenting! Standing room only. Is it tolerability that caused this? 57% completed all cycles. Sizeable pT2 group and no M1NED may have made the population less high risk. @OncoAlert@IMDConline@bmsnews
Congratulations to @CharlesSwanton for an elegant answer to the question of LC causality in never smokers! Opening the possibility of LC prevention with IL 1b inh. Similarly to tobacco exposure, we should reduce PM2.5 air pollution exposure. @myESMO
#Lungcancer awareness month is November! Join us this #LCAM and show your support by either making or buying a white ribbon! Check out here for more white ribbon resources: https://t.co/oTS9MEigkA
Updated @NCCN guidelines recommends genetic testing in all women <50 yrs at breast ca dx.Our study in @JCO_ASCO ⬇️ has shown that this threshold will miss >10% of BRCA1/2 carriers.We need to expand testing to all women under 65 at breast ca dx to identify >95% of BRCA1/2 carriers
Dose matters !!! DESTINY-LUNG02 trial. Same efficacy, less toxicity including pneumonitis in HER2 mut #NSCLC with 5.4 vs 6.4 dose. Should be the standard dose. Please include patient in DESTINY-LUNG04 trial (exp arm dose is 5.4) #ESMO22@OncoAlert